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BACKGROUND: Intracellular phosphoprotein activation significantly regulates cancer progression. However, the significance of circulating
phosphoproteins in the blood remains unknown. We investigated the serum phosphoprotein profile involved in pancreatic cancer
(PaCa) by a novel approach that comprehensively measured serum phosphoproteins levels, and clinically applied this method to the
detection of PaCa.
METHODS: We analysed the serum phosphoproteins that comprised cancer cellular signal pathways by comparing sera from PaCa
patients and benign controls including healthy volunteers (HVs) and pancreatitis patients.
RESULTS: Hierarchical clustering analysis between PaCa patients and HVs revealed differential pathway-specific profiles. In particular,
the components of the extracellular signal-regulated kinase (ERK) signalling pathway were significantly increased in the sera of PaCa
patients compared with HVs. The positive rate of p-ERK1/2 (82%) was found to be superior to that of CA19-9 (53%) for early stage
PaCa. For the combination of these serum levels, the area under the receiver-operator characteristics curves was showing significant
ability to distinguish between the two populations in independent validation set, and between cancer and non-cancer populations in
another validation set.
CONCLUSION: The comprehensive measurement of serum cell signal phosphoproteins is useful for the detection of PaCa. Further
investigations will lead to the implementation of tailor-made molecular-targeted therapeutics.
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Pancreatic cancer (PaCa) is an exceptionally devastating disease
with a 5-year survival rate of only 5% (Jemal et al, 2009). One of
the most crucial reasons for the poor prognosis is the lack of early
diagnostic markers for PaCa. To overcome pancreatic malignancy,
there is an urgent need to discover highly sensitive markers for
early detection. The widely used serum-circulating marker for
PaCa, carbohydrate tumour-associated antigen 19-9 (CA19-9), is
not sufficiently accurate to be used as a diagnostic marker. CA19-9
is elevated in only approximately 65% of individuals with a
resectable PaCa, and is also frequently elevated in patients with
various benign pancreaticobiliary disorders; notably cholestasis
and chronic pancreatitis (PT) (Goggins, 2005). Thus, CA19-9 is not
recommended for diagnostic purposes (Locker et al, 2006).
In the past decade, various approaches have been used to
discover new cancer serum biomarkers, and have identified some
attractive molecular targets as diagnostic or prognostic markers
for PaCa (Gold et al, 2006; Takano et al, 2008). Despite the
identification of candidate proteins that have high diagnostic
sensitivity and specificity in validation tests, translating these
research findings to useful and reliable clinical tests still remains
difficult (Zhang et al, 2004; Petricoin et al, 2002).
Protein phosphorylation is one of the most prominent, and
intensively studied post-translational modifications in biological
systems. Specifically, better understanding of the defective or
hyperactive signalling pathways in cancer cells has been the major
focus of mechanistic studies of cancer progression and differentia-
tion, as well as in the identification of candidate markers
for diagnosis and therapeutic targets (Petricoin et al, 2005).
Ultimately, the signalling pathways promote tumourigenesis
through the coordinated phosphorylation of proteins that directly
regulate protein synthesis, cell-cycle progression and of transcrip-
tion factors that regulate the expression of genes involved in these
processes. Although these intracellular signalling pathways and its
components (activated or inactivated forms) that are closely
associated with cancer progression are among the most thoroughly
studied in molecular cancer research, there has been little
understanding of the dynamic nature of these circulating proteins
in the bloodstream.
Because blood continuously perfuse the tissues of the body, it is
thought to contain most human proteins (at least in fragment
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sforms), thereby supplying the richest and most detailed source of
information about the physiological state of the body (Anderson
et al, 2004). Thus, blood has a pivotal role in early disease
detection. The turnover of proteins in cells requires calculated
degradation processes to secrete intact or fragment forms into
blood and to also remove proteins that are no longer necessary or
those that have lost functional capabilities. Meanwhile, it is
thought that a large part of those human serum-circulating
proteins that promote signal transduction in cells may be
cleaved by degradation of endogenous substrates and proteases
(Villanueva et al, 2006a,b; Schilling and Knapp, 2008). Taken
together, it is worthwhile for the early cancer detection to elucidate
the molecular networks in cancerous cells and the microenviron-
ments, and to investigate the dynamic nature of those cancer-
related phosphorylated proteins including the fragments in
circulating blood.
The Bio-Plex suspension array using specific antibodies and
based on the principle of flow cytometry is a high-throughput
technology that can measure multiple proteins in low sample
volumes. Immunoaffinity approaches, particularly phospho-
specific antibodies that recognise low abundance phospho-
tyrosine, -serine and -threonine residues in the specific epitopes,
have been used to assess phosphoprotein enrichment. In further
developing this technology, it is possible to detect the phospho-
specific sites of the parent molecule and its degraded fragments in
serum as early diagnostic markers by comprehensive analysis in
cancer patients. This technology has overcome a critical problem
for the translational application of proteomics by developing a
procedure that is convenient with high sensitivity, specificity and
reproducibility. Moreover, this may also provide important
information regarding the activation state of kinase-driven
signalling networks in each cancer patient for therapeutic target
selection with the advantage that the screen is less invasive.
In this study, we analysed the circulating cell signalling
phosphoproteins in sera using this proteomic approach and
investigated whether these protein levels are useful for detection,
as early diagnostic serum markers for PaCa, in combination with
comprehensive and hierarchical cluster analyses. Our study results
indicate that the use of this new approach will lead to new insights
in proteomic cancer biology and in the potential development of
patient-tailored combination molecular targeting therapy, through
elucidation of the phosphoprotein networks in serum from cancer
patients.
MATERIALS AND METHODS
Patient samples
We selected four populations of patients with PaCa, PT and
healthy control volunteer (HV). Blood samples were obtained from
all patients who were diagnosed with PaCa and PT in the Chiba
University Hospital, Chiba, Japan, from November 2002 to March
2009, and the samples were also obtained from HVs in the Chiba
University Hospital and the Kashiwado Hospital, Chiba, Japan.
Sera were collected from 26 patients with PaCa and 25 HVs for the
training set, from 80 patients with PaCa and 68 HVs for validation
set 1, furthermore, to assess the diagnostic ability of discriminating
between cancer and non-cancer populations, sera of 35 patients
with PaCa as a cancer group, and 40 patients with PT as well as 48
HVs as a non-cancer group were selected to match for age for
validation set 2 (Table 1). All patients were histologically
confirmed as PaCa. The characteristics of 141 patients with PaCa
are summarised in Table 2. All blood samples were processed
according to a standardised protocol, and serum sample aliquots
were frozen until the subsequent analysis. None of the patients
received any therapeutic treatments, such as radiation, chemo-
therapy or operation, until serum samples were collected.
The ethics committee for each institute approved the protocol.
Written informed consent was obtained from all patients and HVs.
Bio-Plex phosphoprotein suspension assay
Phosphorylated proteins in serum were detected with a Bio-Rad
phosphoprotein immunoassay kit using the Bio-Plex 200 suspen-
sion array system (Bio-Rad Laboratories, Hercules, CA, USA). The
human serum diluent buffer was added up to 50ml to the eight-fold
diluted samples, 50ml aliquots of each of the diluted samples were
plated in the 96-well filter plate, coated with anti-phosphoprotein
antibody-coupled beads, and incubated for 16h on a platform
shaker at 300r.p.m. at room temperature. The wells were vacuum
Table 1 Summary of all participants
Experimental groups
(number of patients) Sex (M/F) Age (mean±s.d.)
Training set (n¼51)
Pancreatic cancer (n¼26) 17/9 65.2±8.0
Healthy volunteer (n¼25) 17/8 52.0±10.6
Validation set 1 (n¼148)
Pancreatic cancer (n¼80) 48/32 62.9±10.8
Healthy volunteer (n¼68) 41/27 54.1±6.8
Validation set 2 (n¼123)
Pancreatic cancer (n¼35) 21/14 63.6±8.8
Pancreatitis (n¼40) 38/2 61.7±8.8
Healthy volunteer (n¼48) 32/16 62.4±7.3
Abbreviations: F¼female; M¼male.
Table 2 Characteristics of patients with pancreatic cancer
Variables
Training set
(n¼26)
Validation set 1
(n¼80)
Validation set 2
(n¼35)
Tumor stage
T1 0 3 8
T2 2 2 4
T3 21 47 12
T4 2 10 2
TX 1 18 9
Nodal status
N0 7 16 16
N1 17 41 10
NX 2 23 9
Metastasis
M0 24 53 30
M1 2 27 5
UICC stage
IA 0 2 8
IB 1 2 4
IIA 6 11 3
IIB 16 32 10
III 1 6 5
IV 2 27 5
Resection status
R0 12 38 21
R1 7 9 5
R2 4 6 0
RX 3 27 9
Abbreviations: RX¼unresectable case; UICC¼Union Internationale Contre le
Cancer.
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sfiltered and washed, 1ml of detection antibodies (25 ) was added,
vortexed and incubated for 30min. After additional vacuum
filtration and washing of the wells, 0.5ml streptavidin–PE (100 )
was added to each well and allowed to incubate for 10min.
The wells were again vacuum filtered and washed, 125mlo f
re-suspension buffer was added and incubated for 30s. Data
acquisition and analysis were performed using Bio-Plex Manager
software version 5.0. The data of measurement by the Bio-Plex 200
suspension array system are presented in the Supplementary
Information (Supplementary Figure S1; Supplementary Table S1).
For the training set, 18 targeted phosphorylated (p-) proteins
were measured using Bio-Plex 200 suspension array system in the
comprehensive phosphoprotein analysis. Focusing on the
more promising candidate proteins, phospho-mitogen-regulated
kinase 1 (p-MEK1), phospho-extracellular signal-regulated kinases
1/2 (p-ERK1/2) and those total proteins; we measured (t-) for the
further validation sets.
Immunohistochemistry
Paraffin-embedded tissues were cut into 4mm-thick serial sections
and were de-paraffinised. Serial section slides were placed in citric
acid buffer (10mmoll
 1,p H6 . 0 )w i t h0 . 2 %T w e e n2 0a n db o i l e di na
microwave oven (2 6min) to retrieve the antigen. The slides were
then rinsed and blocked in a 3% H2O2 solution with methanol for
10min, before being incubated overnight at 41C with the primary
antibodies; rabbit anti-phospho-MEK1/2 monoclonal antibody (Cell
Signaling Technology, Beverly, MA, USA) and rabbit anti-phospho-
ERK1/2 (p44/42 MAPK) monoclonal antibody (Cell Signaling
Technology) (1:50 and 1:200 dilution respectively). SignalStain
Antibody Diluent (Cell Signaling Technology) was used as the
dilution buffer. They were then rinsed in PBS, and incubated for
60min with secondary antibody labelled with streptoavidin–biotin–
peroxidase (DAKO LSABþ kit; DakoCytomation, Glostrup, Denmark).
The bound complex was visualised using diaminobenzidine liquid
chromogen and counterstained with hematoxylin.
Comprehensive and hierarchical clustering analyses of the
training and validation sets
To investigate the similarity of expression patterns, we performed
hierarchical clustering analysis using R statistical software (version
2.8.0). Before analysis, the expression levels were standardised
using Z-transformation (mean¼0 and variance¼1) for each
protein. We then used Euclidian distance of expression patterns
for calculation of distance matrices (i.e., one for proteins and the
other for samples) between each variable, as well as the average
linkage method for clustering analysis.
Multivariate logistic regression using selected proteins
To assess the diagnostic ability for PaCa patients and controls, we
performed univariate and multivariate logistic regression analyses
using p-ERK1/2, CA19-9 and the combination of p-ERK1/2 and
CA19-9 models. Receiver-operating characteristic (ROC) curves
and area under the curve (AUC) based on the prediction results of
the obtained regression models were calculated by the R statistical
software.
Statistical analysis
Statistical analyses were performed using the appropriate tests as
indicated. P-values o0.05 were considered statistically significant.
To compare the positive rate for detecting early stage pancreatic
malignancies, we determined the positive levels of p-ERK1/2 in
disease patients by the reference values in each of the respective
three sets (Solberg, 1987). The reference values in the three
sets were calculated using reference limits corresponding to
0.95 fraction of the distribution, that is the upper limit of the
95% confidence interval (CI), in the three respective healthy
control groups. For CA19-9, a cut-off value of 37IUml
 1 was used,
according to the manufacturer’s specifications for the reference
range of CA19-9.
RESULTS
Circulating phosphoproteins levels are increased in sera
from patients with pancreatic cancer
To detect new biomarkers characteristic of the PaCa patients, we
comprehensively first measured the 18 major targeted cell
signalling phosphoproteins levels in sera of the training set using
the Bio-Plex suspension array. Many of the target phosphoproteins
levels were increased significantly in sera from PaCa patients
compared with the HVs (see detail of the experimental data in
Supplementary Table S2). Hierarchical clustering analysis showed
that the relative differential expressions of circulating phospho-
proteins clearly distinguished PaCa patients from HVs (Figure 1A).
Six candidate phosphoproteins (p-ERK1/2: Po0.00001, p-MEK1:
Po0.0005, phospho-p90 ribosomal S6 kinase (p-p90RSK):
Po0.0001, phospho-cAMP response element binding protein
(p-CREB): Po0.00001, p-Akt: Po0.00005 and p-IkB-a:
Po0.0001; Mann–Whitney U-test) were significantly increased
in sera from patients with PaCa compared with the HVs.
As shown in the lower panel of Figure 1A, similar cluster
structures were obtained in the clustering analysis of these six
phosphoproteins. Subclass analysis separated the PaCa patients
into two groups, based on hierarchical clustering of the six
candidate marker levels, and revealed that each of the two groups
correlated well with the groups that had favourable and unfavour-
able prognoses (P¼0.07; log-rank test; Figure 1B). These were also
closely correlated with each protein belonging to the phosphati-
dylinositol-3-OH kinase/Akt, NF-kB and ERK signalling pathways
that are crucial for cancer survival (Figure 1C).
Two of these proteins, p-ERK1/2 and p-MEK1, are shown in
Figure 2A. Of particular interest, four of the six phosphoproteins
were proteins directly associated with the most popular pathway of
pancreatic carcinogenesis, the Ras/Raf/MEK/ERK signalling
cascade to two proteins (p-p90RSK and p-CREB) that are directly
or indirectly phosphorylated by ERK. Surprisingly, the results
indicate that p-ERK1/2 levels in serum showed a significantly
positive correlation with p-MEK1 levels (r¼0.57, Po0.00002;
Pearson’s correlation coefficient test) as well as p-ERK, which
would theoretically be dependant on the activity of MEK and is in
turn promoted by an entire series of upstream events (Figure 2B).
Therefore, we mainly selected two key molecules, ERK and MEK,
to investigate the expression of those phosphorylated and total
proteins in sera for further validation analyses by Bio-Plex assay.
Confirmation of target phosphoprotein serum levels by
western blot analysis
To confirm the results obtained from Bio-Plex assay, we assessed
the expression of phosphoproteins both sera from patients with
PaCa and HVs by immunoprecipitation assay and western blot
analysis. Corresponding with Bio-Plex data, increased p-ERK1/2
expression levels were confirmed by western blot analysis in sera
from three PaCa patients and one HV (see detail of the methods
and experimental data in Supplementary Figure S2).
Activated p-ERK and p-MEK are expressed in pancreatic
cancer cells
To examine the potential source of the activated ERK and MEK in
serum, we performed immunohistochemical staining for these
phosphoproteins in resected PaCa tissues. As shown in Figure 2C,
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sboth activated p-ERK and p-MEK expression levels were clearly
positive in pancreatic ductal carcinoma cells. The p-ERK and
p-MEK expression was localised to the neoplastic epithelial cells
and some stromal cells especially surrounding the ductal
carcinoma cells. Activated p-ERK was found in both the nucleus
and cytoplasm of cancer cells. Conversely, p-MEK expression was
not found in the nucleus of cancer cells, but stained intensely in
the cytoplasm of cancer cells.
Both p-ERK and p-MEK levels in sera were significantly
correlated with the positive staining of pancreatic
cancer tissues
Next, we investigated whether the two phosphoproteins levels in
sera correlated with the positive staining in PaCa tissues. Among
26 PaCa patients in training set, 23 patients (R0, R1 and R2; all
resectable cases) were analysed by immunohistochemical staining
HV
p-HSP27
p-p38 MAPK
p-p90RSK
p-STAT3
PaCa
p-Akt
p-STAT2
p-IRS-1
p-JNK
p-c-Jun
p-TrkA
p-Histone H3
p-p70 S6 Kinase
p-ERK1/2
p-MEK1
p-CREB
p-IkB-a
p-p53
p-GSK-3a/b
–2SD
SD
Expression index
p-Akt
p-CREB
p-IkB-a
p-MEK1
p-ERK1/2
p-p90RSK
1
(n=11)
P=0.07(log rank)
0.8
0
0.2
0.4
0.6
A
c
c
u
m
u
r
a
t
i
v
e
 
r
a
t
e
0 1 02 03 04 0
Overall survival time (months)
(n=11)
GFR
Ras Cytoplasm
(PI3K)
Various growth factors
ERK
p-ERK
p-MEK
p-CREB
p90RSK
p-ERK
p-p90RSK
p-Akt
CREB
p-NFkB
(IKKa)
NFkB
p-IkBa
Nucleus
CREB
p-CREB (MSK)
Raf MEK
p-p90RSK
2SD 0
–SD
Figure 1 Hierarchical clustering of phosphoprotein expression profiles in the training set. (A) Healthy volunteers (HVs) are denoted in light blue in the
vertical side bar, and pancreatic cancer (PaCa) patients are denoted in orange. Dendrograms show the classification determined by hierarchical clustering
analysis of 18 targeted phosphoproteins. As shown in Expression index, red and blue in the matrix indicate relative overexpression and underexpression
respectively (s.d.; standard deviation). The hierarchical clustering analysis clearly distinguished the two groups; the majority of PaCa patients are found in the
right side, whereas HVs are mainly located in the left side of the heat map (upper panel). The profiles of six candidate circulating phosphoproteins associated
with PaCa are revealed by hierarchical clustering analysis (lower panel). Subclass analysis separated the PaCa patients into two groups based on the
candidate phosphoproteins. The distinction of the two groups is indicated by the blue and purple lined boxes. (B) Kaplan–Meier analysis revealed that each
of the two groups (blue and purple lines) distinguished by the hierarchical clustering analysis was well matched with a favourable and unfavourable prognosis
of PaCa patient groups. (C) The schema of the correlation between candidate phosphoproteins by cell signal transduction in the intracellular environment.
The crucial interaction among these molecules allows the cancer to proliferate and differentiate through representative cell signalling pathways.
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sof the PaCa tissues. The 23 patients were divided into two groups
based on positive or negative staining in PaCa cells, 16 (69.6%) of
23 cases were p-ERK-positive staining, and 19 (82.6%) cases were
p-MEK-positive staining. Notably, as shown in Figure 2D, both
p-ERK and p-MEK levels in sera were significantly correlated with
the positive staining of PaCa tissues respectively (p-ERK: Po0.008,
p-MEK: Po0.02; Mann–Whitney U-test).
Both phospho- and total-ERK1/2 simultaneously increase
with a positive correlation in sera of patients with
pancreatic cancer
To confirm the results obtained from the training set, we measured
and analysed both ERK and MEK serum levels with an increased
sample size in validation set 1. Similar results were obtained, that
both p-ERK1/2 and p-MEK1 levels were significantly increased in
sera from PaCa patients compared with that of HVs for vali-
dation set 1 (p-ERK1/2; Po0.00001, p-MEK1; Po0.00001:
Mann–Whitney U-test; Figure 3A). In addition, t-ERK1/2 levels
were also significantly more upregulated in sera from PaCa
patients compared with that of HVs in validation set 1
(Po0.00001; Mann–Whitney U-test). Of particular interest, both
p- and t-ERK1/2 levels increased simultaneously with a positive
correlation in sera from PaCa patients (r¼0.38, Po0.0004;
Pearson’s correlation coefficient test) (figure not shown).
Phospho-ERK1/2 level in serum excels in the detection of
pancreatic cancer
To estimate the cell signalling phosphoprotein, p-ERK1/2, as a
novel serum biomarker to detect PaCa patients, we calculated the
ROC curves, which correlate the true- and false-positive rates
(sensitivity and 1 specificity) between PaCa patients and HVs. The
area under the ROC curve (AUC) was 0.94 for p-ERK1/2, and
concerning with other phosphoproteins, the AUCs were 0.79 for
p-MEK1, 0.81 for p-p90RSK, 0.86 for p-CREB and 0.83 for p-Akt in
the training set. To validate and compare the abilities of serum
markers for the diagnosis of PaCa, we constructed ROC curves for
p-ERK1/2, CA19-9 and the combination of two serum levels in
validation set 1. The respective AUC was 0.88 for p-ERK1/2, 0.91
for CA19-9 and 0.96 for the combination p-ERK1/2 and CA19-9
(Figure 3B).
The positive rate of serum p-ERK1/2 in the disease groups was
calculated using the reference values determined according to the
upper limit of 95% CI in the three respective healthy control
groups. In all three sets of this study, only five patients showed
negative levels for both p-ERK1/2 and CA19-9. For CA19-9,
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Figure 2 Serum phosphoproteins increased in PaCa patients compared to HVs in the training set. (A) Circulating p-ERK1/2 and p-MEK1 levels in sera are
significantly greater in PaCa patients than HVs. (B) Linear regression with p-ERK1/2 and p-MEK1 levels reveals a significant, positive correlation in the training
set. (C) Immunostaining for p-ERK and p-MEK in PaCa tissues (original magnification,  200). Note that expression of the two phosphoproteins is evident in
the cancerous cytoplasm (arrows in p-ERK and p-MEK) and nucleus (arrowhead in p-ERK), and is also found in stromal cells surrounding the ductal
carcinoma cells. (D) Both p-ERK and p-MEK levels in sera were significantly correlated with the positive staining of PaCa tissues (p-ERK: Po0.008, p-MEK:
Po0.02; Mann–Whitney U-test).
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s39 false-negative patients were mostly picked up as p-ERK1/2-
positive (87.2%) patients with PaCa (Table 3). These results
indicate that the combination of p-ERK1/2 and CA19-9 achieved
sufficiently high sensitivity and specificity to diagnose PaCa
accurately by supplementing the low sensitivity of CA19-9 that
was caused by deficiency of Lewis antigens and so on.
Combination of p-ERK1/2 and CA19-9 levels is superior
discriminatory power between cancer and non-cancer
populations
In validation set 2, we compared and analysed the differential
protein expression of six candidate phosphoproteins levels in sera
from PaCa, PT patients and HVs. Hierarchical clustering analysis
indicated that the populations of PT patients were located diffusely
but approximately in between the HVs and PaCa patient groups
(Figure 3C).
Furthermore, to assess the discriminatory power of serum
p-ERK1/2 levels, we measured to compare p-ERK1/2 and CA19-9
levels in sera of PaCa patients and age-matched benign controls
including PT patients. Phospho-ERK1/2 levels were significantly
increased in sera among three populations (Po0.00001; Kruskal–
Wallis test; Figure 3D), and between cancer and non-cancer
populations (Po0.00002; Mann–Whitney U-test). To discriminate
cancer from non-cancer groups, we performed multivariate logistic
regression analysis using p-ERK1/2 and CA19-9. As a result, both
p-ERK1/2 (odds ratio: 13.4, 95% CI: 2.14–83.6, P¼0.0056; Wald
test) and CA19-9 (odds ratio: 3.67, 95% CI: 1.86–7.22, P¼0.0002;
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Figure 3 Confirmation of the results obtained from the training set for validation set 1. (A) The similar result of the training set shows that both circulating
p-ERK1/2 and t-ERK1/2 levels were significantly increased in sera from PaCa patients compared with that of HVs for validation set 1. (B) The ROC analyses
were performed for the serum levels of p-ERK1/2, CA19-9 and a combination of p-ERK1/2 and CA19-9 between PaCa patients and HVs. The respective
AUCs were 0.88 for p-ERK1/2 level, 0.91 for CA19-9 level and 0.96 for the combination of p-ERK1/2 and CA19-9 levels. Comparing among three
populations in validation set 2. (C) Serum levels of six candidate phosphoproteins were able to distinguish among the three populations (HV, PT and PaCa)
by hierarchical clustering analysis. The analysis distinguished the three groups; the majority of PaCa patients are found on the right side, whereas PT are
located diffusely in the approximate centre and HVs are mainly located on the left side of the heat map. (D) Circulating p-ERK1/2 levels in sera were
significantly differenced among three populations (PaCa, PT and HVs) (Po0.00001; Kruskal–Wallis test). (E) The ROC analyses were performed for the
serum levels of p-ERK1/2 and CA19-9 between cancer (PaCa) and non-cancer (HVs and PT) populations. The respective AUCs were 0.75 for p-ERK1/2
level and 0.70 for CA19-9 level and 0.84 for the combination of p-ERK1/2 and CA19-9 levels.
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sWald test) were identified as significant variables for the detection
of PaCa. For distinguishing between cancer and non-cancer
groups, the respective AUC was 0.75 for p-ERK1/2 and 0.70 for
CA19-9, and the AUC was 0.84, showing high ability to distinguish
between cancer and non-cancer groups, for the combination of the
two serum levels (Figure 3E). These results suggest the combina-
tion of p-ERK1/2 and CA19-9 levels is better discriminatory power
compare to CA19-9 alone between cancer and non-cancer
populations.
Circulating p-ERK1/2 is a potential novel marker for early
stage of pancreatic cancer
To emphasise the diagnosis of early stage of patients with
pancreatic malignancy, we found that the sensitivity of serum
p-ERK1/2 levels for predicting stage I PaCa in our study
population was 82% (14 out of 17 patients with stage IA or IB
cancers had elevated p-ERK1/2), whereas only 9 out of 17 (53%)
patients showed elevated CA19-9. These results suggest that the
measurement of serum p-ERK1/2 levels could be particularly
helpful in the detection of early stage PaCa.
DISCUSSION
The results reported herein show that the measurement of
circulating signal transduction proteins in serum led to the
detection of PaCa. To elucidate molecules related to PaCa
progression, we used a new strategy based on the multiplexed
cell signalling of phosphoproteins in serum by hierarchical
clustering analysis. To detect pre-malignant tumour or early stage
malignancies, it is necessary to be able to assess very low abundant
substances that are likely produced by tumour itself (i.e.,
fragments of cellular components, endo- or exogenous protease
and secretion derived from tumour) (Villanueva et al, 2006a,b),
the microenvironment of the tumour–host interface (Iacobuzio-
Donahue et al, 2002) and the host immune response to tumour
(Koomen et al, 2005). Recently, it was reported that both lymphatic
vessel compression with resultant functional abnormalities and
elevated interstitial fluid pressure occur during the early stages of
carcinogenesis (Hagendoorn et al, 2006). These insights have
formed the theoretical foundation for the detection of early stages
of cancer.
Biological fluids, such as serum, are a readily obtainable source
of potential cancer biomarkers that are shed or secreted by cancer
cells, and are produced as a consequence of humoral immunity
(Lu et al, 2008). Serum immerses most tissues in the body and is
therefore likely to contain cell-derived proteins that can provide
dynamic information about various biological processes.
In addition, it is thought that cellular or tissue protein might
likely present as a full-length form or the cleavage fragments that
freely enter circulation by diffusion or convection (Liotta and
Petricoin, 2006).
Concerning proteins as indicators, it has been recognised that
blood protein biomarkers are amplified in the circulatory system
because they accumulate on the high concentration of resident
proteins, such as albumin, and then acquire the longer half-life of
albumin, thereby protecting the bound species from renal
clearance (Lowenthal et al, 2005; Araujo et al, 2008). Lowenthal
et al also indicated that among many individual sequences that
were predicted from albumin-associated proteins in serum from
patients with three stages of ovarian cancer, the predicted
sequences were largely fragments derived from proteins with
diverse biological functions, including crucial cellular signal
transduction factors. Interestingly, the kinds of signal transduction
factors were more numerous in sera from patients with early stage
than in advanced stage of cancer among the identified proteins. In
an recent study, the enrichment of serum phosphopeptides using
the modified particles was successful to identify phosphorylated
peptides that were related to cancer. The profiling of these
degraded fragments has been found to be able to distinguishing
between hepatocellular carcinoma patients and healthy individuals
(Hu et al, 2009). Our current study results are consistent with these
theories of protein amplification and actual identification in the
circulatory system.
The activation of epidermal growth factor receptor (EGFR) and
the various downstream targets, such as Ras, Raf, MEK and ERK,
are deeply implicated in the pathogenesis of PaCa with malignant
transformation and enhanced tumour aggressiveness. In addition,
the signalling cascade is likely crucial for PaCa progression
because K-Ras gene mutations have been found in many
populations of human PaCa specimens. The efficacy of molecular
targeting therapies for PaCa, such as an inhibitor of EGFR tyrosine
kinase, small-molecule inhibitor of Raf kinase and that of the dual
specificity kinase MEK1/2, have recently being evaluated in some
clinical trials, however, the results have not been impressive
(Rinehart et al, 2004; Siu et al, 2006; Moore et al, 2007). The major
reason is considered that the dysregulation or hyperactivity in the
network of intracellular and extracellular signalling pathways is so
complicated with multiplicity that each individual may have a
differential profile even among similar malignancies. It is reason-
able to surmise that to obtain maximum efficacy of molecular-
targeted therapies it is necessary to investigate which pathway is
more highly activated for each cancer patient (Jimeno et al, 2008).
In the near future, our new insights may resolve this problem with
a minimally invasive approach.
This is the first study to show circulating cell signalling
phosphoproteins in blood of PaCa patients. In our experiments,
comprehensive and hierarchical clustering analyses of serum
phosphoproteins between PaCa patients and HVs revealed path-
way-specific profiles, in particular components of the ERK
signalling pathway, and a new method to classify serum
phosphoproteins possibly derived from tumour itself, based on
intracellular signalling portraits. As mentioned above, overcoming
the issue of specificity as well as discovering highly sensitive
markers for early detection are undoubtedly important. We
confirmed that this signature could be used to discriminate not
only between cancer and healthy controls in an independent
validation set but also between cancer and non-cancer populations
in an age-matched sample as another validation set. We also found
that these circulating molecules were potentially useful for the
diagnosis of early stage PaCa. These results suggest that the level of
circulating p-ERK may be associated with early stage of pancreas
carcinogenesis.
Immunohistochemistry of PaCa tissues showed that two target
phosphoproteins, p-ERK and p-MEK, were simultaneously well
expressed during the early stage neoplasms, even in the cancer
cells of non-invasive or minimally invasive ductal carcinoma, as
well as in the advanced stage patients with PaCa. Furthermore,
Table 3 p-ERK1/2-positive rate in CA19-9 false-negative patients with
pancreatic cancer
CA19-9 false
negative (%)
p-ERK1/2-positive in
CA19-9 false negative (%)
Training set 6/26 (23.1) 6/6 (100.0)
Validation set 1 22/80 (27.5) 20/22 (90.9)
Validation set 2 11/35 (31.4) 8/11 (72.7)
Total 39/141 (27.7) 34/39 (87.2)
Abbreviations: CA19-9¼carbohydrate tumour-associated antigen 19-9; p-ERK1/2¼
phospho-extracellular signal-regulated kinases 1/2.
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good correlation with the positive staining of their PaCa tissues.
Taken together, we consider that the major source for the elevation
of cell signal phosphoproteins levels in serum may be cancer cells
that are showing augmented cell signalling.
Subclasses distinguished by hierarchical clustering analysis of
six candidate markers indicated good correlation with the
prediction of the prognosis of PaCa patients in this study. Further
investigation of subclass analysis by hierarchical clustering will
provide fruitful information regarding which factors of cell
signalling phosphoproteins in serum are associated with the
malignant behaviour of PaCa.
PaCa develops as a result of the stimulation and activation of
various growth factor receptors. The continuous stimulation of
these signal transduction pathways leads to increases in both the
activated and inactivated forms of the cell signalling molecules in
the intracellular environments of cancerous cells. The downstream
activation transmits information through post-translational
protein modifications with reversible protein phosphorylation.
Increasing signal molecules that accumulate in the cell trigger
changes in the penetration of cell membrane, which causes the
release of both phosphoproteins and the degraded fragments to
extracellular environments by cellular apoptosis. Once released
from the intracellular environments, those proteins likely lose their
original function, and are then carried to nearby blood vessels, and
circulate freely or with binding to high-affinity transfer proteins in
blood circulatory system. However, further research is needed to
elucidate the sequence of this pathway.
In conclusion, we found cancer-associated cell signal phospho-
proteins in serum using multiplexed cell signalling analysis. The
measurement of circulating phosphoproteins in serum was able to
discriminate between cancer patients and benign controls, and this
new approach was helpful in the early diagnosis of patients with
PaCa. This method shows the feasibility of this analysis, with a less
invasive approach. The next step is to elucidate the profiling of cell
signal activation by these comprehensive and hierarchical cluster-
ing analyses may discriminate subclasses into clinically significant
groups. In the near future, investigations determining the
footprints of circulating phosphoproteins will lead to the clinical
application of this method that will be used for targeted tailor-
made therapeutics.
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